Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities
Phase of Trial: Phase IV
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms EPIC
- Sponsors Abbott Laboratories; AbbVie
- 14 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 May 2016.
- 14 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 May 2016.
- 21 Oct 2015 Planned number of patients changed from 266 to 288, as reported by ClinicalTrials.gov record.